The global graft versus host disease (GvHD) treatment market demand is expected to secure US$ 5,655.37 Million in 2032 while expanding at a CAGR of 8.3%. The market is experiencing a steady growth in corticosteroids and combination therapies for graft-versus-host disease in HCT patients boosting the market for (GvHD) treatment. The market is likely to hold a value of US$ 2,547.86 …
Continue reading “Graft Versus Host Disease (GvHD) Treatment Market Leaders & Key Revenue Pockets”